Related Experiment Video
Updated: Jun 27, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
A pan-HER approach for cancer therapy: background, current status and future development
Zhongdong Huang1, Cathleen Brdlik, Pei Jin
1Receptor BioLogix, Inc., Palo Alto, CA 94303, USA.
Background:
The human EGF receptor (EGFR or HER) family and its cognate ligands contribute significantly to the aggressiveness of many human malignancies, and are therefore therapeutic targets with great clinical potential.
Objective:
Currently approved single-targeted agents, like mAbs, (e.g., trastuzumab, cetuximab, or pertuzumab) or small-molecule tyrosine kinase inhibitors (TKIs, e.g., gefinitib and erlotinib), are limited by their exquisite specificity (mAbs) or lack thereof (TKIs). Therefore, therapeutics are needed that target multiple HER family members and HER ligands to circumvent these limitations.
Methods:
We summarize therapeutic mechanisms of action, analyze tumor resistance to current anti-HER therapies, and introduce a novel pan-HER ligand sequestering agent for cancer treatment.
Conclusion:
RB200, a bispecific (EGFR/HER3) ligand binding trap, has been developed to address the need for a pan-HER therapy in human cancer.
Insights
A new therapy targets multiple human EGF receptor (HER) family members and ligands to improve cancer treatment. RB200, a bispecific ligand trap, offers a novel approach to combatting HER-driven malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- The human EGF receptor (HER) family and its ligands drive cancer aggressiveness.
- Current HER-targeted therapies (mAbs, TKIs) have limitations due to specificity issues.
- There is a clinical need for therapeutics targeting multiple HER family members and ligands.
Purpose of the Study:
- To summarize mechanisms of action for HER-targeted therapies.
- To analyze tumor resistance patterns against current anti-HER treatments.
- To introduce a novel pan-HER ligand sequestering agent for cancer therapy.
Main Methods:
- Review of therapeutic mechanisms.
- Analysis of tumor resistance to existing anti-HER agents.
- Introduction of a novel bispecific ligand binding trap.
Main Results:
- Current single-target agents have limitations in specificity and efficacy.
- Tumor resistance mechanisms necessitate broader therapeutic strategies.
- A novel pan-HER therapy has been developed.
Conclusions:
- RB200 is a bispecific (EGFR/HER3) ligand binding trap.
- RB200 addresses the need for a pan-HER therapy in human cancer.
- This approach offers potential for improved cancer treatment outcomes.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistant Cancers
Treatment Resistent Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

